24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Pharmaceutical
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
21:36
Intel slashes employee bonuses amid financial struggles
16:48
Way off-brand: Israel ranked dead last in global Nation Brands Index
16:27
Innoviz cuts 9% of workforce in latest round of layoffs amid financial struggles
15:09
Deel secures $300M secondary transaction at over $12B valuation, hits $800M revenue run rate
More stories
Buzz
Most popular
Daily
Weekly
1
Intel slashes employee bonuses amid financial struggles
2
Intel pulls the plug on AI chip designed to rival Nvidia
3
Deel secures $300M secondary transaction at over $12B valuation, hits $800M revenue run rate
4
Unicorn AppsFlyer lays off 100 employees in strategic restructuring
5
Bigabid raises $25 million Series A to boost gaming adtech growth
More news
Pharmaceutical
12 stories about Pharmaceutical
Kibbutz-Owned Food Manufacturer Maabarot Bids for Teva’s North Israel Facility
16.10.18
|
Golan Hazani
Last week, Calcalist reported that Teva was nearing the sale of its Kiryat Shmona facility to German pharmaceutical device company B. Braun
Teva Nearing Sale of Israeli Manufacturing Plant
09.10.18
|
Golan Hazani
The pharmaceutical company is negotiating the sale of a manufacturing facility located in the town Kiryat Shmona in the north of Israel
Teva Outsources Manufacturing in Anticipation of Israeli Plant Closure
27.08.18
|
Golan Hazani
The debt-laden drugmaker announced an aggressive reorganization plan in December, consisting of wide-spread asset divestments and layoffs, including in its home country of Israel
Israeli Cannabis Startup InnoCan Pharma Raises $800,000 Via Crowdfunding
27.08.18
|
Lilach Baumer
InnoCan develops medication for psoriasis and muscle and joint pains. Its management team includes former senior executives at Teva and Pfizer
AstraZeneca Signs Deal with Cancer Immunotherapy Company Compugen
03.04.18
|
Lilach Baumer
The deal has the potential to be worth over $200 million for Nasdaq-listed Compugen
Drugmaker Hikma Appoints Former Teva Executive as CEO
20.02.18
|
Asaf Shalev
The appointment of Sigurdur Olafsson comes as Hikma has been struggling to bolster the performance of its generic drugs unit
Merck Group Inaugurates Jerusalem Innovation Lab
07.02.18
|
Lilach Baumer
The new lab is located at Merck subsidiary Qlight Nanotech, acquired by the pharmaceutical company in 2015
Danish Leo Pharma is Launching an Innovation Lab in Israel
04.02.18
|
Lilach Baumer
Established in 2015, Leo Pharma’s innovation lab currently operates in Copenhagen, London, Paris, and Toronto, developing digital health solutions
Following U.S. Bribe Settlement, Teva to Pay $22 Million Fine in Israel
15.01.18
|
Tomer Ganon
Yesterday, the Israeli state attorney settled a suit against the company. In 2016, Teva agreed to pay $519 million to settle anti-bribery violations in the U.S.
Moody’s Downgrades Teva Bond Rating to “Junk”
14.01.18
|
Lilach Baumer
The credit rating agency is following is the steps of Fitch, which did the same in November. Of the “big three,” only S&P Global still rates Teva as investment grade
Pontifax Raises a $240 Million Fifth Fund
01.01.18
|
Meir Orbach
Life sciences-focused venture capital firm Pontifax is expected to invest most of the new fund in the pharmaceutical industry
Teva Might Have Been Better Off as a Smaller Company, new CEO Says
17.12.17
|
Dror Reich
The generic drugs powerhouse is now carrying a $34.7 billion debt—a result of a $40.5 acquisition of Actavis. New CEO Kåre Schultz presented a detailed restructuring plan on Thursday
Previous Articles